August 10th 2020
Jae Park, MD, discusses the benefits of off-the-shelf CAR T-cell therapy in acute lymphoblastic leukemia.
August 7th 2020
Jae Park, MD, discusses considerations for CAR T-cell therapy in relapsed/refractory acute lymphoblastic leukemia.
April 2nd 2020
Jae Park, MD, a hematologist oncologist at Memorial Sloan Kettering Cancer Center, discusses the use of CAR T-cell therapies in patients with acute lymphocytic leukemia.
April 6th 2018
Jae Park, MD, hematologist oncologist, Memorial Sloan Kettering Cancer Center, discusses the potential of CD19-targeted chimeric antigen receptor (CAR) T-cell therapy in adult patients with acute lymphoblastic leukemia (ALL).
December 16th 2014
Jae H. Park, MD, attending physician, Leukemia Service, Memorial Sloan Kettering Cancer Center, discusses a trial presented at the 2014 ASH Annual Meeting that explored CD19-targeted T cells as treatment for patients with relapsed, refractory B- cell ALL.